Marinus Pharmaceuticals, Inc. increased earnings guidance for full year 2024. For the year, company projected U.S. ZTALMY net product revenues to between $33 and $35 million from a range of $32 Million and $34 Million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | +1.53% | 0.00% | -87.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.76% | 73.06M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+13.89% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024